Profile: Pfizer Inc (PFE)
2 Jul 2015
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. The Company's portfolio includes medications and vaccines, as well as consumer healthcare products. Its key biopharmaceutical products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, the Premarin family of products, Eliquis and Xeljanz, among others. The Company's biotechnology products include BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel, among others. The Company's commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. In addition, it focuses on biosimilars. The Company's revenues from biopharmaceutical products contributed approximately 92% of its total revenues in 2014. The Company has collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including Aricept, Enbrel (in the United States and Canada), Spiriva and Rebif. In addition, the Company developed Eliquis in collaboration with Bristol-Myers Squibb Company (BMS).
The Company's Consumer Healthcare business is an over-the-counter (OTC) and healthcare products business that produces two of the Company's consumer healthcare brands (Centrum and Advil). The Consumer Healthcare business holds positions in various geographic markets, such as the United States, China, Canada, Germany, Italy and Brazil. Major categories and product lines in its Consumer Healthcare business include: dietary supplements, pain management, gastrointestinal, respiratory and personal care. Dietary supplements include Centrum brands, including Centrum, Centrum Silver, Centrum Men’s and Women’s, Centrum Specialist, Centrum Flavor Burst, and Centrum Kids; Caltrate, and Emergen-C. Pain management category includes Advil brands, including Advil, Advil PM, Advil Liqui-Gels, Advil Film Coated, Children’s Advil, Infants’ Advil and Advil Migraine, and ThermaCare. Gastrointestinal includes Nexium 24HR/Nexium Control. Respiratory category includes Robitussin, Advil Cold & Sinus, Advil Congestion Relief and Dimetapp. Personal care category includes ChapStick and Preparation H. The Company's Consumer Healthcare products are sold through a variety of channels, including distributors, pharmacies, retail chains, and grocery and convenience stores. In the United States, Pfizer’s Greenstone subsidiary and Pfizer Injectables sell generic versions of Pfizer’s, as well as certain competitors’ oral dosage and sterile injectable pharmaceutical products.
Global Innovative Pharmaceutical segment
The Company's Global Innovative Pharmaceutical segment is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health and include brands, such as Xeljanz, Eliquis and Lyrica (the United States and Japan). GIP has a pipeline of medications in inflammation, cardiovascular/metabolic disease, neuroscience and pain, and rare diseases.
Global Vaccines, Oncology and Consumer Healthcare segment
The Company's Global Vaccines, Oncology and Consumer Healthcare segment focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets several over-the-counter (OTC) products.
Global Established Pharmaceutical segment
The Company's Global Established Pharmaceutical segment includes the brands that have lost market and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in markets and, to a smaller extent, generic pharmaceuticals. Additionally, GEP includes its sterile injectable products and bio similar development portfolio.
235 E 42ND ST
NEW YORK NY 10017-5703
Company Web Links
- Exclusive: Hospira wins French biosimilar drug tender at 45 percent discount
- Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount
- Hospira wins French biosimilar drug tender at 45 pct discount
- PRESS DIGEST- British Business - July 3
- Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets